MannKind Corporation

On #NationalInternDay MannKind would like to celebrate the 19 outstanding interns across our Danbury and Westlake Village sites. During their 8 weeks working at MannKind, our group of interns will receive real-world experience while working with a knowledgeable mentor in their field. Our interns specialize in professions such as clinical research, manufacturing, legal, engineering, and more. We are amazed to see what they have achieved within the laboratory, corporate offices, and through their community volunteer work. We cannot wait for August when we get to see the interns present their projects that have been brewing. #MannKind #SummerInternship2024

MannKind’s headquarters, nestled near the streets where Danbury Mayor Roberto Alves grew up, welcomed him with open arms today. Mayor Alves joined MannKind CEO Michael Castagna and COO Lauren Sabella and their team to tour the Connecticut facility that manufactures innovative therapeutic products such as inhaled insulin. Sharing what MannKind is doing to help patients living with endocrine and orphan lung diseases are special moments in our books. #MannKind #DanburyCT

Super exciting times ahead!

Looking forward to Scotland and conversations at the 7th World Bronchiectasis Conference, July 4-6. MannKind is proud to be an industry partner of #WBConf24 and present a poster on Clofazimine Inhalation Suspension for the treatment of NTM Pulmonary Disease. See you in Dundee! #MannKind #NTM #NTMlungDisease #LungDisease 

MannKind is excited to share positive 17-week results from the INHALE-3 study presented by the INHALE-3 investigational team at the American Diabetes Association’s 84th Scientific Sessions in Orlando today. The study proves inhaled insulin is as effective as usual care (primarily automated insulin delivery pumps or multiple daily injections) for adults living with Type 1 Diabetes meeting the primary endpoint. https://bit.ly/3zeRJTe #MannKind #Diabetes #T1D #ADASciSessions

MannKind is looking forward to the #DData2024 forum on Friday, June 21 in Orlando. As part of the “No Pump, No Problem? How Non-Pumpers Can Benefit from Data-Driven Care” panel, Dr. Roy Beck, founder of Jaeb Center, will lead a discussion on how inhaled insulin fits into the overall landscape of care. #MannKind #Diabetes #T1D #T2D

We’re heading to the #ADASciSessions and look forward to connecting with you! Visit with MannKind and its Clinical Education Team to learn more about inhaled insulin and our latest developments in the management of diabetes. Visit us in in the Exhibit Hall at Booth# 1307.   On Saturday, June 22, you won’t want to miss the 90-minute Symposium sharing 17-week endpoint results from the INHALE-3 study that addresses the common question about Afrezza®: How does inhaled insulin fare when compared head-to-head with usual care of Multiple Daily Injections (MDI)/non-automated pumps and automated insulin pumps? Jaeb Founder Dr. Roy W. Beck will moderate the session with presentations from INHALE-3 Study Protocol Chair Dr. Irl B. Hirsch and the investigational team. Eventgoers can enjoy the presentation beginning at 8:00 a.m. (ET) in W320 Chapin Theatre – Orange County Convention Center in Orlando.   #MannKind #Diabetes #T1D

MannKind is excited for the 17-week endpoint results from the INHALE-3 study to be shared Saturday, June 22 during a 90-minute Symposium and livestream for attendees at the American Diabetes Association’s 84th Scientific Sessions. The presentations will be delivered by INHALE-3 Study Protocol Chair Dr. Irl B. Hirsch and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck. The results will speak to the common question about Afrezza®: How does inhaled insulin fare when compared head-to-head with usual care of Multiple Daily Injections (MDI)/non-automated pumps and automated insulin pumps? Eventgoers can enjoy the presentation beginning at 8:00 a.m. (ET) in W320 Chapin Theatre – Orange County Convention Center in Orlando. MannKind will host Booth# 1307 in the Exhibit Hall throughout the Sessions where one can learn more about Afrezza as well as visit MannKind’s Clinical Education Team who will be available for scientific exchange in the medical section of the booth. #MannKind #Diabetes #T1D #ADASciSessions

The greatest spectacle in racing gets underway this weekend at the Indianapolis Motor Speedway. When the green flag flies on the 108th Running of the Indy 500, MannKind will be cheering on the No. 24 Dreyer Reinbold Racing / Cusick Motorsports car. Driver Conor Daly – who is living with type 1 diabetes – will be behind the wheel. Tune in Sunday at 12:30pm ET on NBC to see who will drink the milk. #MannKind #Diabetes #T1D #Indy500 @ConorDaly22 @DreyerReinboldRacing @CusickMotorsports

It’s almost time for the 2024 American Thoracic Society Conference and Respiratory Innovation Summit! MannKind is looking forward to seeing the @atscommunity in San Diego soon. Come visit with our pulmonary team at Booth# CT3 to learn more about the exciting developments in our orphan lung pipeline. MannKind was recently granted Fast Track designation for our Phase 3 study of the potential of Clofazimine Inhalation Suspension (MNKD-101) to treat NTM and are proceeding with a Phase 1 study of Nintedanib DPI for fibrotic lung diseases. The latest information on our pulmonary efforts can be found here: https://bit.ly/3Wio8lg #MNKD #NTM #Pulmonary #PulmonaryFibrosis #ATS2024 and #RIS2024